We are live on ! Find out more
SONX

Sonendo, Inc.

Delisted

SONX was delisted on the 21st of November, 2023.

33 hedge funds and large institutions have $24.4M invested in Sonendo, Inc. in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

11% less funds holding

Funds holding: 3733 (-4)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

60% less capital invested

Capital invested by funds: $61.3M → $24.4M (-$36.9M)

Holders
33
Holders Change
-4
Holders Change %
-10.81%
% of All Funds
0.56%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
7
Increased
11
Reduced
5
Closed
10
Calls
Puts
Net Calls
Net Calls Change

SONX Hedge Fund Activity: Q2 2022 in Review

33 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Sonendo, Inc. (SONX) for Q2 2022, worth a combined $24.4M — down 60% from $61.3M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of SONX and 7 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 11 added.

The largest buyer was Millennium Management, adding an estimated $1.58M. The largest seller was OrbiMed, cutting an estimated $3.32M.

  • 33 institutional investors held Sonendo, Inc. (SONX) as of Q2 2022, down from 37 in Q1 2022.
  • Funds reported $24.4M of Sonendo, Inc. stock for Q2 2022, down 60% quarter-over-quarter.
  • 7 funds opened new Sonendo, Inc. positions in Q2 2022 and 10 closed out, a net change of -3 holders.
  • The largest Sonendo, Inc. buyer in Q2 2022 was Millennium Management, an estimated $1.58M added.
  • The largest Sonendo, Inc. seller in Q2 2022 was OrbiMed, an estimated $3.32M sold.

Based on aggregated 13F filings for Q2 2022.